Irena Philipova

Dr. Irena Philipova

orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 1995 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
SMStefan Matile
Stefan Matile
NBNina Berova
Nina Berova
KNKoji Nakanishi
Koji Nakanishi
SNSnejana Novkova
Snejana Novkova
IPIrena Philipova
Irena Philipova
BBBlagoy Blagoev
Blagoy Blagoev

1 September 2015 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
MAMariyana Atanasova
Mariyana Atanasova
Georgi StavrakovGeorgi Stavrakov
Georgi Stavrakov
IPIrena Philipova
Irena Philipova
Dimitrina Zheleva-DimitrovaDimitrina Zheleva-Dimitrova
Dimitrina Zheleva-Dimitrova
Nikola YordanovNikola Yordanov
Nikola Yordanov
Irini DoytchinovaIrini Doytchinova
Irini Doytchinova

23 July 2020 in Molecules
Verified
Journal Article
Open access
PDF file
Georgi StavrakovGeorgi Stavrakov
Georgi Stavrakov
IPIrena Philipova
Irena Philipova
ALAtanas Lukarski
Atanas Lukarski
MAMariyana Atanasova
Mariyana Atanasova
Dimitrina Zheleva-DimitrovaDimitrina Zheleva-Dimitrova
Dimitrina Zheleva-Dimitrova
Irini DoytchinovaIrini Doytchinova
Irini Doytchinova
Galantamine (GAL) and curcumin (CU) are alkaloids used to improve symptomatically neurodegenerative conditions like Alzheimer’s disease (AD). GAL acts mainly as an inhibitor of the enzyme acetylcholinesterase (AChE). CU binds to amyloid-beta (Aβ) oligomers and inhibits the formation of Aβ plaques. Here, we combine GAL core with CU fragments and design a combinatorial library of GAL-CU hybrids as dual-site binding AChE inhibitors. The designed hybrids are screened for optimal ADME properties and BBB permeability and docked on AChE. The 14 best performing compounds are synthesized and tested in vitro for neurotoxicity and anti-AChE activity. Five of them are less toxic than GAL and CU and show activities between 41 and 186 times higher than GAL.

1 January 2018 in Journal of Enzyme Inhibition and Medicinal Chemistry
Verified
Journal Article
Open access
Irini DoytchinovaIrini Doytchinova
Irini Doytchinova
MAMariyana Atanasova
Mariyana Atanasova
IVIva Valkova
Iva Valkova
GSGeorgi Stavrakov
Georgi Stavrakov
IPIrena Philipova
Irena Philipova
IDIvan Dimitrov
Ivan Dimitrov
The inhibition of the enzyme acetylcholinesterase (AChE) increases the levels of the neurotransmitter acetylcholine and symptomatically improves the affected cognitive function. In the present study, we searched for novel AChE inhibitors by docking-based virtual screening of the standard lead-like set of ZINC database containing more than 6 million small molecules using GOLD software. The top 10 best-scored hits were tested in vitro for AChE affinity, neurotoxicity, GIT and BBB permeability. The main pharmacokinetic parameters like volume of distribution, free fraction in plasma, total clearance, and half-life were predicted by previously derived models. Nine of the compounds bind to the enzyme with affinities from 0.517 to 0.735 µM, eight of them are non-toxic. All hits permeate GIT and BBB and bind extensively to plasma proteins. Most of them are low-clearance compounds. In total, seven of the 10 hits are promising for further lead optimisation. These are structures with ZINC IDs: 00220177, 44455618, 66142300, 71804814, 72065926, 96007907, and 97159977.

1 April 1999 in Tetrahedron: Asymmetry
Verified
Journal Article
Closed access
IPIrena Philipova
Irena Philipova
Vladimir DimitrovVladimir Dimitrov
Vladimir Dimitrov
SSSvetlana Simova
Svetlana Simova

1 December 2013 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Georgi StavrakovGeorgi Stavrakov
Georgi Stavrakov
VVVioleta Valcheva
Violeta Valcheva
IPIrena Philipova
Irena Philipova
Irini DoytchinovaIrini Doytchinova
Irini Doytchinova